Watch CEO of Immuta, Matthew Carroll's fireside chat with Alessandra De Almeida, Executive Director of Data Management & Governance at Merck, exploring Merck's transformative data management journey.

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

If we compare that back to 2021, that's almost a tripling of the number of assets that we have. And so from a commercial perspective, the reason I get excited is because the impact we can have on ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...

Moderna Inc. aims to reduce its research and development budget by about 20% over the next three years as the biotech tries ...

Feel free to distribute or cite this material, but please credit OpenSecrets. For permission to reprint for commercial uses, such as textbooks, contact OpenSecrets: [email protected] ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year. For years drug companies have sought to beat the therapy to no avail.

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

The trial will assess the asset in patients with diabetic macular oedema. Credit: NTshutterth / Shutterstock. MSD (Merck & Co) and its wholly-owned subsidiary EyeBio have announced the start of the ...